The chairman is eager to send a message for the coming year.
Release time:
2021-02-10
seize the day and seize the hour for development, and it is urgent to improve the ability.
enterprise needs to redouble its efforts. chairman
earnestly hopes to send a message to the group company's 2020 annual summary and commendation conference held on February 3, Jiang xiaomeng, secretary of the party Committee and chairman of the group company, made the topic "seize the hour for development" in view of the market situation and existing problems faced by the company in that year, the summary speech of the meeting of "ability is urgent", from three aspects of analysis and elaboration, the company's work in 2021 put forward requirements.
The current achievements are not easy to come by, and the future risks are still in sight. Jiang Xiaomeng pointed out that the peak has made good achievements in the 13th Five Year Plan period, which is not only the result of persisting in strengthening the main business, grasping the layout and attaching importance to management, but also the achievements brought about by the joint efforts of all the peak people. However, the current China is facing a century of unprecedented changes, the world pattern has undergone great changes, the new coronary pneumonia epidemic global pandemic to accelerate the evolution of this great change, economic globalization encountered a countercurrent, economic downturn, and is entering a period of turbulent change, the economic situation is changing very fast. Under the new pattern of taking the domestic big cycle as the main body and the domestic and international double cycle, enterprises must grasp the "new rhythm" of the market and lay a good "advance quantity". Enterprises that meet the status quo and rest on their laurels will be eliminated by the market at any time. Judging from the situation of the peak itself, with the progress of the industry and the integration of enterprises, the existing advantages of the two main businesses have been overtaken or are being overtaken. What we can do is to establish a correct and realistic development direction as the premise, seize opportunities, make scientific layout, take the initiative to innovate, vigorously develop, solve problems in development through development, and enhance the core competitive advantages of enterprises through innovation.
Grasp the development and seize every minute. It is urgent to improve the ability. Jiang Xiaomeng believes that the next five years will be the historical intersection of the implementation of the 14th Five-Year Plan and the two 100-year goals. The economic work conferences of the Central Committee, Zhejiang Provincial Committee and Jinhua Municipal Committee have pointed out the direction for economic and social development at their respective levels. Enterprise managers must deeply understand the spirit of the relevant meetings and find out the focus of future development. Improve the organizational competitiveness, product competitiveness, innovation competitiveness, cultural competitiveness and talent competitiveness of the group company in an all-round way. From the perspective of the two main businesses of the peak, the problem of cement overcapacity has existed for a long time, and the best way to solve the problem of excess is merger and reorganization and transformation and upgrading to improve industrial concentration and market competitiveness. The peak cement sector should also seize the current opportunity to step up the layout. In the pharmaceutical industry, with the in-depth implementation of policies such as medical insurance negotiations and volume procurement, the competitive pressure of production enterprises has increased sharply. Peak Pharmaceutical must seize the time to build the cost and quality advantages of the production system in an all-round way, and use the speed, quality, curative effect and exclusive advantages in the field of innovative drugs to create the comparative competitive advantage of Peak Pharmaceutical.
The future of the enterprise is promising. We need to redouble our efforts. Jiang Xiaomeng pointed out that for the peak, only by doing familiar industries, doing good work, and making products with core competitiveness can we get better development. How to recreate advantages? The cement sector should speed up the rational layout, seize the advantages of resources, improve labor productivity through intelligent transformation, reduce costs and efficiency, reduce emissions through continuous upgrading of processes, and establish competitive advantages through the extension of the industrial chain such as aggregate production and solid hazardous waste treatment. The pharmaceutical industry should strengthen the introduction of innovative drugs and exclusive drugs to obtain incomparable product advantages. Taking advantage of the existing conditions for the integration of bulk drugs and preparations, the cost of centralized products should be minimized to ensure the competitive advantage in joint centralized procurement. Taking advantage of the tightening of environmental protection management and the tightening of approval for the production of bulk drugs, the cake of pharmaceutical intermediates and bulk drugs should be enlarged to create the second peak pharmaceutical industry.
For the specific work in 2021, Jiang Xiaomeng has made key requirements on the following aspects: strictly implement the company's annual work plan, layer upon layer of responsibilities, and ensure the completion of the target; Establish the concept of "everything for sales", improve the quality of operation, enhance the stickiness of customers, realize the advancement of sales, continuously improve the level of customer service, and achieve high returns with efficient management, high-quality service and high-quality products; Grasp the market demand, take the initiative to seize opportunities, speed up the layout of the cement industry and enhance competitiveness; adhere to innovation-driven and technology-led, seize the commanding heights of intelligent manufacturing, cement enterprises should build intelligent factories with high standards, and the pharmaceutical industry should strengthen the research and development of new drugs, speed up the progress of research and development, improve the level of research and development, and seize the market with innovative drugs; deepen strategic cooperation with universities and scientific research institutes, and use brains to attract wisdom to achieve mutual benefit and win-win; continue to promote green and environmentally friendly production to ensure safe and standardized growth; promote corporate culture, promote the growth of employees, and enhance employees' sense of identity and belonging to the company; strengthen the leadership of party building, establish a spirit of responsibility, and cultivate the idea of employees and the company to advance and retreat together, and share honor and disgrace, Create a good atmosphere of clean and upright.
Jiang Xiaomeng stressed that the realization of the grand blueprint for the future of the peak requires the joint efforts of every peak person. He hoped that all cadres and employees would show greater energy and courage in their future work to create a better tomorrow for the peak and themselves. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31